Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation

A. Shirwaikar, L.S. Prabu, D.C. Kumar, R. Kumar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new simple, sensitive spectrophotometric method in ultraviolet region has been developed for the determination of granisetron hydrochloride in bulk drug and its pharmaceutical formulation. Granisetron hydrochloride exhibited maximum absorbance at 302 nm with apparent molar absorptivity 1.3258X 104 in methanol. It obeyed Beer's law in the concentration range of 6 - 20 mcg/mL Results of the analysis were validated statistically and by recovery studies.
Original languageEnglish
Pages (from-to)606-609
Number of pages4
JournalIndian Drugs
Volume44
Issue number8
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Granisetron
Drug Compounding
Methanol
Pharmaceutical Preparations

Cite this

Shirwaikar, A., Prabu, L. S., Kumar, D. C., & Kumar, R. (2007). Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation. Indian Drugs, 44(8), 606-609.
Shirwaikar, A. ; Prabu, L.S. ; Kumar, D.C. ; Kumar, R. / Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation. In: Indian Drugs. 2007 ; Vol. 44, No. 8. pp. 606-609.
@article{9649ea42f2a9483ba5e494278c3eb69c,
title = "Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation",
abstract = "A new simple, sensitive spectrophotometric method in ultraviolet region has been developed for the determination of granisetron hydrochloride in bulk drug and its pharmaceutical formulation. Granisetron hydrochloride exhibited maximum absorbance at 302 nm with apparent molar absorptivity 1.3258X 104 in methanol. It obeyed Beer's law in the concentration range of 6 - 20 mcg/mL Results of the analysis were validated statistically and by recovery studies.",
author = "A. Shirwaikar and L.S. Prabu and D.C. Kumar and R. Kumar",
note = "Cited By :1 Export Date: 10 November 2017 CODEN: INDRB Correspondence Address: Shirwaikar, A.; Manipal College of Pharmaceutical Sciences, Manipal - 576 104, India; email: arunshirwaikar@yahoo.co.in References: Sanger, G.J., Nelson, P.R., Selective and functional 5-Hydroxytryptamine 3 receptor antagonism by BRL 43694 (1989) Eur. J. Pharmacol., 159, pp. 113-124; Upward, J.W., Arnold, B.D.C., Link, C., Pierce, D.M., Allen, A., Tasker, T.C.G., The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist (1990) European Journal of Cancer, 26 (SUPPL. 1), pp. S12-S15; Carmichael, J., Cantwell, B.M.J., Edwards, C.M., Zussman, B.D., Thompson, S., Rapeport, W.G., Harris, A.L., A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: Correlation with anti-emetic response (1989) Cancer Chemotherapy and Pharmacology, 24 (1), pp. 45-49; Jiang, Y., Lin, M., Fan, G., Chen, Y., Li, Z., Zhao, W., Wu, Y., Hu, J., Rapid determination of granisetron in human plasma by liquid chromatography coupled to tandem mass spectrometry and its application to bioequivalence study (2006) J. Pharm. & Biomed. Anal., , Epub ahead of print; Aapro, M., Granisetron: An update on its clinical use in the management of nausea and vomiting (2004) Oncologist, 9 (6), pp. 673-686. , DOI 10.1634/theoncologist.9-6-673; Huang, C.-T., Chen, C.-F., Tsai, T.-H., Pharmacokinetics of granisetron in rat blood and brain by microdialysis (1999) Life Sciences, 64 (21), pp. 1921-1931. , DOI 10.1016/S0024-3205(99)00143-5, PII S0024320599001435; Boppana, V.K., Simultaneous determination of granisetron and its 7-hydroxy metabolite in human plasma by reverse phase high performance liquid chromatography utilizing fluorescence and electrochemical detection (1995) J. Chromatogr. A., 692, pp. 195-202; Huang, C.T., Chen, C.F., Chen, K.C., Tsai, T.H., Simultaneous measurement of blood and brain microdialysates of granisetron in rat by high performance liquid chromatography with fluorescence detection (1998) J. Chromatogr. B., 716, pp. 251-255; Wada, I., Satoh, M., Takeda, T., Nakabayashi, T., Honma, T., Saitoh, H., Takada, M., Hirano, K., A rapid assay of granisetron in biological fluids from cancer patients (1998) Biological and Pharmaceutical Bulletin, 21 (5), pp. 535-537; McElvain, J.S., Vandiver, V.J., Eichemeir, L.S., Validation of a reverse phase HPLC method for directly quantifying the enantiomersof MDL 74,156, the primary metabolite of dolasetron mesylate in human plasma (1997) J. Pharm. Biomed. Anal., 15, pp. 513-521; Pinguet, F., Bressolle, F., Martel, P., Salabert, D., Astre, C., High-performance liquid chromatographic determination of granisetron in human plasma (1996) Journal of Chromatography B: Biomedical Applications, 675 (1), pp. 99-105. , DOI 10.1016/0378-4347(95)00335-5; Allen, A., Asgill, C.C., Pierce, D.M., Upward, J., Zussman, B.D., Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects (1994) European Journal of Clinical Pharmacology, 46 (2), pp. 159-162; Cupissol, D., Bressolle, F., Adenis, L., Carmichael, J., Bessell, E., Allen, A., Wargenau, M., Romain, D., Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease (1993) Journal of Pharmaceutical Sciences, 82 (12), pp. 1281-1284. , DOI 10.1002/jps.2600821221; Capacio, B.R., Byers, C.E., Jackson, T.K., Matthews, R.L., An HPLC method for the determination of granisetron in guinea pig plasma (1993) Journal of Analytical Toxicology, 17 (3), pp. 151-155; Boppana, V.K., Miller Stein, C., Schaefer, W.H., Direct plasma liquid chromatographic tandem mass spectrometric analysis of granisetron and its 7-hydroxy metabolite utilizing internal surface reversed phase guard columns and automated column switching devices (1996) J. Chromatogr. B., 678, pp. 227-236; Nirogi, R.V.S., Kandikere, V.N., Shukla, M., Mudigonda, K., Maurya, S., Boosi, R., Quantification of granisetron in human plasma by liquid chromatography coupled to electrospray tanden mass spectrometry (2006) Biomed. Chromatogr., , Epub ahead of print",
year = "2007",
language = "English",
volume = "44",
pages = "606--609",
journal = "Indian Drugs",
issn = "0019-462X",
publisher = "Indian Drug Manufacturers' Association",
number = "8",

}

Shirwaikar, A, Prabu, LS, Kumar, DC & Kumar, R 2007, 'Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation', Indian Drugs, vol. 44, no. 8, pp. 606-609.

Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation. / Shirwaikar, A.; Prabu, L.S.; Kumar, D.C.; Kumar, R.

In: Indian Drugs, Vol. 44, No. 8, 2007, p. 606-609.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Spectrophotometric determination of granisetron hydrochloride from bulk and its formulation

AU - Shirwaikar, A.

AU - Prabu, L.S.

AU - Kumar, D.C.

AU - Kumar, R.

N1 - Cited By :1 Export Date: 10 November 2017 CODEN: INDRB Correspondence Address: Shirwaikar, A.; Manipal College of Pharmaceutical Sciences, Manipal - 576 104, India; email: arunshirwaikar@yahoo.co.in References: Sanger, G.J., Nelson, P.R., Selective and functional 5-Hydroxytryptamine 3 receptor antagonism by BRL 43694 (1989) Eur. J. Pharmacol., 159, pp. 113-124; Upward, J.W., Arnold, B.D.C., Link, C., Pierce, D.M., Allen, A., Tasker, T.C.G., The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist (1990) European Journal of Cancer, 26 (SUPPL. 1), pp. S12-S15; Carmichael, J., Cantwell, B.M.J., Edwards, C.M., Zussman, B.D., Thompson, S., Rapeport, W.G., Harris, A.L., A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: Correlation with anti-emetic response (1989) Cancer Chemotherapy and Pharmacology, 24 (1), pp. 45-49; Jiang, Y., Lin, M., Fan, G., Chen, Y., Li, Z., Zhao, W., Wu, Y., Hu, J., Rapid determination of granisetron in human plasma by liquid chromatography coupled to tandem mass spectrometry and its application to bioequivalence study (2006) J. Pharm. & Biomed. Anal., , Epub ahead of print; Aapro, M., Granisetron: An update on its clinical use in the management of nausea and vomiting (2004) Oncologist, 9 (6), pp. 673-686. , DOI 10.1634/theoncologist.9-6-673; Huang, C.-T., Chen, C.-F., Tsai, T.-H., Pharmacokinetics of granisetron in rat blood and brain by microdialysis (1999) Life Sciences, 64 (21), pp. 1921-1931. , DOI 10.1016/S0024-3205(99)00143-5, PII S0024320599001435; Boppana, V.K., Simultaneous determination of granisetron and its 7-hydroxy metabolite in human plasma by reverse phase high performance liquid chromatography utilizing fluorescence and electrochemical detection (1995) J. Chromatogr. A., 692, pp. 195-202; Huang, C.T., Chen, C.F., Chen, K.C., Tsai, T.H., Simultaneous measurement of blood and brain microdialysates of granisetron in rat by high performance liquid chromatography with fluorescence detection (1998) J. Chromatogr. B., 716, pp. 251-255; Wada, I., Satoh, M., Takeda, T., Nakabayashi, T., Honma, T., Saitoh, H., Takada, M., Hirano, K., A rapid assay of granisetron in biological fluids from cancer patients (1998) Biological and Pharmaceutical Bulletin, 21 (5), pp. 535-537; McElvain, J.S., Vandiver, V.J., Eichemeir, L.S., Validation of a reverse phase HPLC method for directly quantifying the enantiomersof MDL 74,156, the primary metabolite of dolasetron mesylate in human plasma (1997) J. Pharm. Biomed. Anal., 15, pp. 513-521; Pinguet, F., Bressolle, F., Martel, P., Salabert, D., Astre, C., High-performance liquid chromatographic determination of granisetron in human plasma (1996) Journal of Chromatography B: Biomedical Applications, 675 (1), pp. 99-105. , DOI 10.1016/0378-4347(95)00335-5; Allen, A., Asgill, C.C., Pierce, D.M., Upward, J., Zussman, B.D., Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects (1994) European Journal of Clinical Pharmacology, 46 (2), pp. 159-162; Cupissol, D., Bressolle, F., Adenis, L., Carmichael, J., Bessell, E., Allen, A., Wargenau, M., Romain, D., Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease (1993) Journal of Pharmaceutical Sciences, 82 (12), pp. 1281-1284. , DOI 10.1002/jps.2600821221; Capacio, B.R., Byers, C.E., Jackson, T.K., Matthews, R.L., An HPLC method for the determination of granisetron in guinea pig plasma (1993) Journal of Analytical Toxicology, 17 (3), pp. 151-155; Boppana, V.K., Miller Stein, C., Schaefer, W.H., Direct plasma liquid chromatographic tandem mass spectrometric analysis of granisetron and its 7-hydroxy metabolite utilizing internal surface reversed phase guard columns and automated column switching devices (1996) J. Chromatogr. B., 678, pp. 227-236; Nirogi, R.V.S., Kandikere, V.N., Shukla, M., Mudigonda, K., Maurya, S., Boosi, R., Quantification of granisetron in human plasma by liquid chromatography coupled to electrospray tanden mass spectrometry (2006) Biomed. Chromatogr., , Epub ahead of print

PY - 2007

Y1 - 2007

N2 - A new simple, sensitive spectrophotometric method in ultraviolet region has been developed for the determination of granisetron hydrochloride in bulk drug and its pharmaceutical formulation. Granisetron hydrochloride exhibited maximum absorbance at 302 nm with apparent molar absorptivity 1.3258X 104 in methanol. It obeyed Beer's law in the concentration range of 6 - 20 mcg/mL Results of the analysis were validated statistically and by recovery studies.

AB - A new simple, sensitive spectrophotometric method in ultraviolet region has been developed for the determination of granisetron hydrochloride in bulk drug and its pharmaceutical formulation. Granisetron hydrochloride exhibited maximum absorbance at 302 nm with apparent molar absorptivity 1.3258X 104 in methanol. It obeyed Beer's law in the concentration range of 6 - 20 mcg/mL Results of the analysis were validated statistically and by recovery studies.

M3 - Article

VL - 44

SP - 606

EP - 609

JO - Indian Drugs

JF - Indian Drugs

SN - 0019-462X

IS - 8

ER -